Journavx was approved by the FDA in late January.
Pershing is hopeful it’ll make an impact in reducing addiction but wants to see the new drug in use before casting a final judgment. “When oxycodone was released, Purdue Pharma told everyone this was ...
FDA approves first non-opioid pain treatment in two decades, providing new hope
Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...
pharmaphorum6d
Latigo raises $150m for non-opioid painkiller push
Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...
Le Lézard4d
Ark Clinical Research at the Forefront of Advancing Non-Opioid Pain Research
The FDA's landmark approval of Journavx (suzetrigine)?the first non-opioid pain reliever in over two decades?represents a breakthrough in pain management. This breakthrough underscores the urgent need ...
Fierce Biotech6d
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...
BioSpace3d
Purdue Files for Bankruptcy Anew to Support $7.4B+ Opioid Settlement
The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...